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a skilled nursing facility (SNF) (1.3[5.4] v 0.9[5.3]; p0.044) was longer on average for
DIS patients. DIS patients had higher ER AD-related costs compared to CON pa-
tients ($135[680] v $53[343] p0.011). CONCLUSIONS: Significantly less AD-related
health care utilization and costs were associated with continued D23 use compared
to patients who discontinued. More patients who continued therapy had 60 days
on donepezil 10mg before starting the D23 treatment vs DIS patients, suggesting
patients receive  60 days of 10 mg prior to initiating D23.
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HOSPITAL PHARMACY’S UNMET NEEDS FOR THE MANAGEMENT OF MULTIPLE
SCLEROSIS
Balaña M1, Lahoz R2, Monte E3, Lorente L3, García Fernández J4, Garcia Monsalve A5,
Olatz Ibarra M6, Granell M1, Blanco J1
1Novartis Farmaceutica, Barcelona, Barcelona, Spain, 2Novartis Farmaceutica, Barcelona, Spain,
3Hospital Universitario La Fe, Valencia, Valencia, Spain, 4C. M. de Orense, Orense, Orense, Spain,
5Hospital Vega Baja, Orihuela, Alicante, Spain, 6Hospital Galdakao, Galdakao, Bizkaia, Spain
OBJECTIVES: To evaluate the management of Spanish patients with multiple scle-
rosis (MS), to assess the unmet needs at the hospital pharmacy and the treatment
adherence fulfilled by MS patients treated with disease-modifying therapies (DMT).
METHODS: Non-interventional and multicenter study that recruited 237 patients
with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) treated
with DMT. Pharmacists completed a questionnaire on management actions and
unmet needs. Adherence was assessed using an adaptation of the Morisky-Green
test. RESULTS: Mean age of patients was 40.19.4 years (65.8% women). Average
time from diagnosis was 7.55.6 years, 95.4% RRMS, 61.2% with no relapses during
last year. Most patients presented EDSS grade 0-2.5 (62.4%). Overall patient adher-
ence was 77.1%. Treatment adherence was significantly higher among patients
with no relapses (82.9% vs 67.4%, p0.05) and among those 40 years (85.1% vs
68.3%, p0.05). 21.1% of pharmacists do not have adequate educational materials
and in 16% of cases there was no adequate space to assure confidentiality. Specific
protocol to monitor adverse events exists only in 21% of pharmacies and to monitor
adherence in 32%. Pharmacists emphasized as major unmet needs: educational
material, adherence training, staff and workload. According to main needs, there
was a trend towards lower adherence at hospitals with higher workload (68.6% vs
80.2%; p0.167) and with lack of educational materials (75.2% vs 84.6%; p0.435).
There were no adherence differences depending on the existence of available
space for training (76.9% vs 78.6%; p0.890) or between gender (84.1% men vs. 73.6%
women; p0.195). In 2 out of 10 cases (19.8%), a discrepancy exists between phar-
macist perception on adherence and Morisky-Green evaluation. CONCLUSIONS:
An improvement of educational materials and operational protocols regarding
workload is a requirement at hospital pharmacies to provide adequate follow-up
and to ensure adherence by MS patients in Spain.
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OBJECTIVES: To assess the health-related quality of life (HRQoL) of young onset
Parkinson’s Disease (PD) people. METHODS: An online survey (2011) of PD people
65 years at diagnosis included demographics, disease management and the As-
sessment of Quality of Life (AQoL). AQoL utility score was calculated where 1.00
represented full and 0.00 death equivalent HRQoL. Disease severity was classified
by Hoehn & Yahr Stages (H&Y). RESULTS: There were 254 participants. Mean diag-
nosis age was 50 years (SD 9); mean time since diagnosis was 6 years. PD was mild
for most participants (n  115, 65, 46, 11 and 4 for H&Y 1 to 5 respectively). The
mean AQoL utility was 0.54 (SD  0.26), which was below the 50-59 years popula-
tion norm (0.80, SD 0.24). HRQoL deterioration was monotonic by H&Y level: 0.67
for Level 1, 0.55 Level 2, 0.36 Level 3 and 0.10 (Levels 4/5). For those aged 20-39 years
at diagnosis the mean AQoL score was 0.41; for 40-49 years 0.50; for 50-59 years 0.58;
and for 60 years it was 0.68 (p0.01). Regarding time since diagnosis, for those
with recent diagnosis (0-2 years) the mean AQoL score was 0.61; 0.63 for those
diagnosed 3-5 years previously; 0.50 for those diagnosed 6-10 years previously; and
0.35 for those diagnosed 11 years previously (p0.01). AQoL scores varied by
gender (females’ mean AQoL 0.59, males’ 0.51, p0.01) and labourforce partic-
ipation (working  0.64, not working  0.39, not in the labourforce  0.50, p0.01).
There were no significant differences by age or relationship. Multivariate analysis
revealed, after adjustment, the significant predictors of AQoL scores were H&Y
classification (p0.01) and diagnosis age (p0.02). CONCLUSIONS:HRQoL of young
onset patients deteriorates as PD progresses. Further research is needed to see if
this can be ameliorated through interventions.
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OBJECTIVES: To describe health state values (utilities) in Alzheimer’s disease (AD)
patients and their caregivers by disease severity. METHODS: GERAS is a prospec-
tive, multi-centre, non-interventional cohort study in France, Germany and the UK,
enrolment October 2010-October 2011. Patients presenting within the normal
course of care who were55 years, diagnosed with probable AD (NINCDS-ADRDA),
not institutionalised and with an informal caregiver were categorised according to
MMSE score as mild (26-21), moderate (20-15) or severe (14 or less) AD. Caregivers
completed the EQ-5D to assess their own health-related quality of life and as prox-
ies for the patient. The UK population-based tariff was used to produce health state
values ranging from 1 (perfect health) to 0 (dead). RESULTS: The study cohort
included 1497 AD patients (38% mild, 32% moderate and 31% severe AD) and their
caregivers (n419 France, n552 Germany and n526 UK) with a mean (SD) patient
age of 77.6 (7.7) years (77.3 mild; 77.8 moderate; 77.6 severe) and 55% female (48%
mild; 57% moderate; 61% severe; p0.001). Caregivers had a mean (SD) age of 67.3
(12.0) years, 64% female and 66% of caregivers were the spouse of the AD patient.
Patient mean (SD) health state values differed significantly based on MMSE cate-
gorisation; mild 0.71 (0.24), moderate 0.64 (0.27) and severe 0.51 (0.34); (p0.001).
Health state values did not statistically differ between caregivers based on MMSE
categorisation [mean (SD) scores for mild 0.82 (0.20), moderate 0.81 (0.21) and se-
vere 0.79 (0.26); p0.069]. CONCLUSIONS: Health state values from the GERAS
study differentiate in AD patients based on MMSE severity, although are higher
than expected. Caregiver values do not statistically separate using the same cate-
gorisation. Health state values from this large cohort of European patients provide
new data for economic evaluation of AD treatments.
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THE MEASUREMENT OF QUALITY OF LIFE IN CHILDREN WITH CYSTIC FIBROSIS
WITH USING RUSSIAN VERSION OF HEALTH UTILITY INDEX (HUI)
QUESTIONNAIRE
Gorinova Y, Simonova O, Vinyarskaya I, Samsonova M, Chernikov V
FSBI, Moscow, Russia
OBJECTIVES:Advances in the management and care of patients with cystic fibrosis
(CF) has led to the majority of patients surviving into adulthood. Whether this
longevity has added quality years to the lives of CF patients is a question which
needs to be addressed. The aim of quality of life (QoL) measurement in CF should be
to quantify and evaluate the impact of both the disease and its treatments on the
wider aspects of the patient’s life. Pilot study was conducted to determine utility
indexes in children with CF using russian version of health utility index question-
naire (HUI).METHODS: Forty-five CF children 6-17 years with moderate and severe
forms of CF interviewed using HUI questionnaire version 15Q, while children over
12 years responded on their own (self assessment), information about children
under 12 years was obtained from parents (proxy assessment) .Version translated
into russian language and has been adapted. Questionnaire designed to assess QoL
and to determine the indexes used in the future indicator for calculating quality
adjusted life years. QoL assessment was carried out on systems HUI 2 and 3. Single-
attribute utility scores and multi-attribute utility scores evaluated corresponding
to each system, ranges from 0 to 1. RESULTS: Single-attribute utility scores index
HUI 3: Vision – 1, Hearing - 1; Speech - 0.96; Cognition - 0.93, Ambulation - 0.98,
Dexterity- 0.98, Emotions-0.96;Pain–0.94. Single-attribute utility scores index HUI
2: Sensation - 0.93; Mobility - 0.99; Cognition - 0.93; Self-care - 0.94; Emotion - 0.92;
Pain - 0.95. In patients with severe and moderate form of CF significant difference
of utility indexes was revealed in Ambulation (g0,011), Pain (g0,008), Mobility
(g0,011) and Emotions (p0.024). CONCLUSIONS: Russian version of HUI ques-
tionnaire showed its accessibility and results can be used in scientific, clinical and
economic studies to assess QoL in children. Ambulation, pain and emotion have
more influence on health status in CF children.
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OBJECTIVES: To evaluate the effect of dalfampridine extended release (D-ER; sus-
tained-, modified-, prolonged-release fampridine outside the US) on utility scores
in multiple sclerosis (MS) patients, estimated using two equations mapping the
12-item MS Walking Scale (MSWS-12) individual item scores to the Euroqol 5-Di-
mension (EQ-5D).METHODS:Data from MS-F203, a randomized trial of D-ER, 10mg
twice daily in MS patients, were used to calculate utility scores with two equations
mapping MSWS-12 item scores to the EQ-5D (one derived in a North American [NA]
registry, the other a United Kingdom [UK] registry). MS-F203 participants were
categorized as D-ER responders (a priori definition of consistent improvement on
the Timed 25-Foot Walk), D-ER nonresponders, or placebo. Mean change in utility
from baseline to each double-blind treatment evaluation (visits 3-6 occurring at
post-randomization weeks 2, 6, 10, 14) and each off-drug follow-up evaluation
(visits 7-8 occurring at weeks 16, 18) were calculated as effect sizes (ESs). RESULTS:
Using the NA-derived equation, D-ER responders demonstrated improvement in
utility vs. placebo or D-ER nonresponders, respectively; starting at week 6 (mean
difference in ES0.37, p0.01; ES0.40, p0.01) and maintained at weeks 10
(ES0.26, p0.17; ES0.31, p0.03) and 14 (ES0.48, p0.01; ES0.34, p0.04). Im-
provements were not apparent after D-ER discontinuation (p0.05 at weeks 16 and
18). Using the UK-derived equation, improvement was seen in D-ER responders vs.
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